Class IIReported 2026-01-14

Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL, Moxifloxacin 0.6 mg/ 0.6 mL) Single-Use Intraocular Injection, Imprimis NJOF, LLC., 1705 Route 46 West, Unit 6B, Ledgewood, NJ 07852. NDC 71384-746-06.

Recalled by Imprimis NJOF, LLC

Reason for Recall

Presence of particulate matter - Glass like particles.

Recall Number

D-0251-2026

Classification

Class II

Status

Ongoing

Category

drug

Initiated

2025-12-18

Reported

2026-01-14

Distribution

U.S Nationwide

Code Info

Lot: 25JAN033A, 25JAN033B, Expires: 02/12/2026.

Source: openFDA enforcement report. WhichRecall is not affiliated with the FDA. See our disclaimer.